Targeted, better-tolerated oral PDE4 inhibitors are an unmet need in inflammatory bowel disease (IBD) PALI-2108 demonstrates in ex vivo studies;…
SAN FRANCISCO, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel…
Accomplished Finance and Commercial Leader Brings Extensive Life Sciences ExpertiseCAMBRIDGE, Mass., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Alkeus Pharmaceuticals, Inc.…
TORONTO, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics…
Phase 3 registrational trials evaluating petosemtamab in combination with pembrolizumab in 1L and petosemtamab monotherapy in 2/3L r/m HNSCC enrolling…
Late-breaking presentation highlights the pTau217 assay as an effective and efficient tool to screen participants for ALTITUDE-AD that reduces unnecessary…
Burlington, Ontario--(Newsfile Corp. - October 30, 2024) - Rapid Dose Therapeutics Corp. (CSE: DOSE) ("RDT" or the "Company") is pleased…
Company to host a conference call tomorrow at 8:00 a.m. ET NEWTON, Mass., Oct. 30, 2024 /PRNewswire/ -- Karyopharm Therapeutics…
BURLINGTON, Mass., Oct. 30, 2024 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) today announced the launch of a long-read Whole Genome…
"Discover High-Growth Opportunities Across Leading Sectors, With BCC Research Highlighting Industries Primed for Up to 20% Annual Returns" BOSTON, Oct.…